Fisetin and Quercetin as Senolytics: What Human Trial Data Reveals
Neil Tuckwell·Science writer covering the biology of aging. Turns cutting-edge anti-aging research into stories you'll want to read over morning coffee.··8 min read
Fisetin and Quercetin as Senolytics: What Human Trial Data Reveals
There are aging cells sitting in your body right now that refuse to die, and researchers think clearing them out might be one of the most promising strategies in longevity science. Two plant-derived compounds, fisetin and quercetin, have moved from petri dishes into human clinical trials as the lead candidates for doing exactly that.
What the early trial data shows is both genuinely exciting and more nuanced than the headlines suggest. This article unpacks the human evidence: what was measured, what changed, and where the science still has real gaps.
What Are Senolytics and How Do Fisetin and Quercetin Fit In?
Senescent cells are sometimes called "zombie cells." They stop dividing but do not die. Instead, they release a steady stream of inflammatory signals known as the senescence-associated secretory phenotype, or SASP. Over time, SASP-driven inflammation is thought to contribute to conditions ranging from kidney disease to pulmonary fibrosis[8].
A senolytic is any agent that selectively kills these zombie cells while leaving healthy ones alone. The concept gained traction after researchers at Mayo Clinic discovered that dasatinib combined with quercetin could clear senescent cells in mice and extend their healthy lifespan[8]. Fisetin, a related flavonoid found in strawberries, followed as a second candidate with its own profile.
Both compounds work by disrupting the BCL-2 and BCL-XL anti-apoptotic pathways, the survival signals that allow senescent cells to resist programmed cell death[8]. The key difference: quercetin appears to work across multiple cell types when paired with dasatinib, while fisetin is more selective and effective against senescent endothelial cells but less so against fibroblasts or preadipocytes[8]. Most human trials use short "burst" doses of two to four days rather than daily supplementation, because senescent cells take two to four weeks to re-accumulate after clearance[2][8].
What the First Human Trials Found
Frequently Asked Questions
This content is for informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any supplement or making changes to your health regimen.
NT
Neil Tuckwell
Science writer covering the biology of aging. Turns cutting-edge anti-aging research into stories you'll want to read over morning coffee.
Science writer covering the biology of aging. Turns cutting-edge anti-aging research into stories you'll want to read over morning coffee.
senolyticsfisetinquercetincellular-aging
Related Articles
longevity
Longevity Science
NMN vs NR: Choosing the Right NAD+ Precursor for Anti-Aging
NMN and NR both raise NAD+ levels, but their functional benefits differ. Here's what 9 human studies say about which one suits your goals.
Neil Tuckwell·9 min read
The strongest human evidence comes from a 2019 open-label pilot trial published in EBioMedicine by Hickson et al. at Mayo Clinic[1]. Nine adults with diabetic kidney disease received three days of oral dasatinib (100 mg) plus quercetin (1,000 mg). Over the next 11 days, adipose tissue biopsies showed that p16INK4A-positive senescent cells dropped by 35% (p=0.001), SA-beta-galactosidase-positive cells fell by 62% (p=0.005), and CD68-positive macrophages decreased by 28% (p=0.0001)[1]. Circulating inflammatory proteins including IL-1alpha, IL-6, MMP-9, and MMP-12 all declined significantly.
Three days of treatment produced measurable biological changes that persisted nearly two weeks later. That was the first direct human evidence that senolytics can clear senescent cells in living tissue. Think of it like clearing one in three problem buildings from a neighborhood: the block does not become perfect, but the signal that removal changes the environment is real.
A 2023 Phase I randomized pilot trial published in EBioMedicine then tested the same combination in 12 adults with idiopathic pulmonary fibrosis, this time using quercetin 1,250 mg three days per week for three weeks[2]. All 108 planned doses were completed without serious treatment-related adverse events. The trial was too small for efficacy conclusions, but it confirmed tolerability in a vulnerable population.
Epigenetic Age: A Surprising and Complicating Result
A 2024 longitudinal pilot study published in Aging tracked 38 participants across two arms: one receiving dasatinib plus quercetin (DQ), and one receiving dasatinib plus quercetin plus fisetin (DQF) for three days per month over six months[3]. Researchers measured epigenetic aging clocks based on DNA methylation patterns.
The result no one expected: epigenetic age acceleration increased in the DQ arm at the three-month mark (p=6.7x10^-6), and telomere length decreased (p=0.01). Adding fisetin attenuated but did not eliminate these effects[3]. Three participants discontinued the study.
This does not mean senolytics cause faster aging. Epigenetic clocks measure methylation patterns that may respond to cellular turnover in complex, not-yet-understood ways. According to this 2024 study in Aging, the researchers explicitly called for larger, longer trials before drawing conclusions[3]. What it does mean is that biological age markers are not simple readouts, and the story of how senolytic interventions register across different measurement tools is still being written.
Fisetin on Its Own: Where the Data Stands
Fisetin's standalone human efficacy data is thin and mixed. A 2024 pilot study published in Alternative Therapies in Health and Medicine gave 10 healthy adults over 50 a dose of fisetin 500 mg per day for one week each month over six months[4]. The results were uneven: 4 participants showed biological age reductions, 5 showed increases, and 1 showed no change. No adverse events were reported.
The spread likely reflects fisetin's notoriously low oral bioavailability. Rapid glucuronidation and sulfation in the gut mean the dose reaching systemic circulation varies considerably between individuals[8]. An uncontrolled 10-person pilot also cannot say much about efficacy in either direction.
More rigorous data is coming. The TROFFi trial is a Phase II randomized placebo-controlled study testing fisetin 20 mg/kg per day for three consecutive days every 14 days across four cycles in 88 postmenopausal breast cancer survivors, targeting physical function as the primary outcome[5]. The STOP-Sepsis trial is separately testing fisetin in 220 elderly patients with acute sepsis, marking the first time a senolytic has been evaluated in critical care[6]. These trials use doses far higher than early pilots, and the dose-response question for fisetin in humans remains open.
Side Effects and Drug Interactions to Know
Across published human trials, the safety profile is broadly reassuring but not without signals. The IPF trial reported 65 non-serious adverse events in the treatment arm versus 22 in placebo, with sleep disturbances and anxiety most notable[2]. The DQF longitudinal study saw one participant discontinue due to nausea, representing 5.3% of that arm[3]. The standalone fisetin pilot reported zero adverse events in its 10 participants[4].
Drug interactions are a more significant concern than side effects alone. Quercetin inhibits the CYP3A4 enzyme pathway, and dasatinib is a CYP3A4 substrate, meaning quercetin may elevate dasatinib concentrations[8]. Quercetin also inhibits P-glycoprotein, which affects the absorption of many other drugs[8]. Anyone on cardiovascular medications, immunosuppressants, or anticoagulants would be adding pharmacokinetic interactions that human trials have not yet studied.
Fisetin's bioavailability challenges cut the other direction: unpredictable absorption makes the effective dose hard to gauge, particularly across supplements from different manufacturers. These are not arguments against the compounds, but they are strong arguments for involving a clinician before starting any senolytic protocol.
Practical Guide: Doses and Timing From the Trials
The dosing landscape is not standardized. Different trials have used meaningfully different quercetin doses, and whether 500 mg fisetin per day in an early pilot is comparable to 20 mg/kg per day in Phase II designs has not been resolved in humans.
Here is what each published trial actually used. The DKD pilot used dasatinib 100 mg plus quercetin 1,000 mg for three consecutive days[1]. The IPF trial used dasatinib 100 mg plus quercetin 1,250 mg, three days per week for three weeks[2]. The DQF study used a monthly protocol of dasatinib 50 mg, quercetin 500 mg, and fisetin 500 mg for three days per month over six months[3]. The standalone fisetin pilot used 500 mg daily for one week per month[4]. The Q-CABG cardiac trial tests quercetin 500 mg twice daily peri-operatively for nine days[7].
One pattern runs through all of them: pulsed dosing, not daily supplementation. The biological rationale is that senescent cells take weeks to re-accumulate, so continuous exposure offers no additional benefit and may increase risk[8]. The intermittent regimens in these trials are a deliberate mechanistic design choice, not an optional detail. Quercetin has the strongest pilot evidence but has only been tested alongside dasatinib, a prescription drug. Standalone quercetin or fisetin at senolytic doses in controlled trials with tissue biopsies does not yet exist. Both compounds are subjects of active Phase II trials that should produce clearer answers within the next few years. Consulting a healthcare provider familiar with the current trial landscape is the most practical step for anyone weighing these options.
Frequently Asked Questions
Q. What is a senolytic and how do fisetin and quercetin work as senolytics?
A senolytic selectively induces apoptosis (programmed cell death) in senescent cells while leaving healthy cells alone. Fisetin and quercetin both disrupt BCL-2 and BCL-XL survival pathways that allow senescent cells to persist[8]. Quercetin works across a broader range of cell types when combined with dasatinib, while fisetin is more cell-type-selective[8]. Neither compound has been confirmed as a standalone senolytic with tissue biopsy evidence in adequately powered human trials.
Q. What do human trials actually show for quercetin as a senolytic?
The strongest evidence comes from a 2019 Mayo Clinic pilot in nine adults with diabetic kidney disease, where three days of dasatinib plus quercetin reduced adipose tissue senescent cell markers by 35-62% within 11 days[1]. A 2023 pilot in pulmonary fibrosis patients confirmed feasibility and tolerability[2]. Both trials were small and underpowered for efficacy; larger Phase II studies are underway.
Q. Does fisetin actually work as a senolytic in humans?
The current evidence is inconclusive. A 2024 uncontrolled pilot with 10 participants showed inconsistent results, with 4 showing biological age reductions and 5 showing increases[4]. Phase II trials including TROFFi (88 participants) and STOP-Sepsis (220 participants) are underway and should provide more reliable data[5][6]. Fisetin's low oral bioavailability adds another layer of complexity to interpreting early results.
Q. What are the main safety concerns with senolytic supplements?
Reported side effects in human trials include sleep disturbances and anxiety (elevated in the IPF trial treatment arm) and occasional nausea (one discontinuation in the DQF study)[2][3]. More importantly, quercetin inhibits CYP3A4 and P-glycoprotein, creating interaction risk with many prescription medications[8]. Anyone taking cardiovascular, immunosuppressive, or anticoagulant drugs should review this with a healthcare provider before using these compounds at senolytic doses.
Q. What dose of fisetin or quercetin is used in senolytic trials?
Doses vary across studies. Quercetin has been used at 1,000-1,250 mg per day alongside dasatinib in three-day burst cycles[1][2]. Fisetin has ranged from 500 mg daily in one pilot[4] to 20 mg/kg per day in Phase II designs, which equals roughly 1,400 mg per day for a 70 kg person[5][6]. These doses are significantly higher than standard supplement use, and the pulsed timing is a deliberate feature of the protocol, not optional[8].
References
[1] Hickson LJ et al., "Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease," EBioMedicine, 2019. DOI: 10.1016/j.ebiom.2019.08.069
[2] Nambiar A et al., "Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial," EBioMedicine, 2023. DOI: 10.1016/j.ebiom.2023.104481
[3] Lee E et al., "Exploring the effects of Dasatinib, Quercetin, and Fisetin on DNA methylation clocks: a longitudinal study on senolytic interventions," Aging (Albany NY), 2024. DOI: 10.18632/aging.205581
[4] Lee E and Burns M, "The Effects of Fisetin on Reducing Biological Aging: A Pilot Study," Alternative Therapies in Health and Medicine, 2024. PMID: 39269340
[5] Ji J et al., "A phase II randomized placebo-controlled study of fisetin to improve physical function in breast cancer survivors: the TROFFi study," Therapeutic Advances in Medical Oncology, 2026. DOI: 10.1177/17588359261424668
[6] Silva M and Wacker DA et al., "Senolytics To slOw Progression of Sepsis (STOP-Sepsis): Study protocol for a multicenter, randomized, adaptive allocation clinical trial," Trials, 2024. DOI: 10.1186/s13063-024-08474-2
[7] Dagher O et al., "Design of a Randomized Placebo-Controlled Trial to Evaluate the Anti-inflammatory and Senolytic Effects of Quercetin in Patients Undergoing CABG Surgery," Frontiers in Cardiovascular Medicine, 2021. DOI: 10.3389/fcvm.2021.741542
[8] Kirkland JL and Tchkonia T, "Senolytic drugs: from discovery to translation," Journal of Internal Medicine, 2020. DOI: 10.1111/joim.13141
This content is for informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any supplement or making changes to your health regimen.
